CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Zero-based budgeting assigns every dollar a purpose, ensuring funds exist for surprises while keeping prior goals intact and trackable.
18,035 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A rising pushback against data centers is reshaping the debate over AI infrastructure. This article breaks down what ...
A rising retirement burden and shifting policy outlook are reshaping how Americans view Social Security. Learn what t...
A prominent wealth manager warns that baby boomers with heavy equity in 401(K)s may face a tougher retirement path if...
AI progress hinges not just on GPUs but on the speed and efficiency of data delivery. This deep dive explains why opt...
As companies rush to deploy AI, hundreds of pilots risk wasting resources and diluting strategy. Analysts warn that t...
New York City Mayor Zohran Mamdani engineered a sweeping primary win, elevating a progressive slate and exposing a cr...
Ford bets on human experience to guide AI, tapping 350 veteran engineers to steer its technology push as recalls and ...
A widower inherits a Roth IRA worth $250,000 and learns the earnings may be taxed if withdrawn before the five-year c...
The SpaceX sell-off is showing signs of worsening momentum, but patient investors can still navigate it with a discip...
The first half of 2026 delivered a sharp downturn for Salesforce as AI-driven disruption and market rotation shook th...
A fit, mid-60s couple reevaluates when to claim Social Security as Treasury yields hover near 4.5%, blending safe inc...